---
schema_version: "secwatch.filing_event.v1"
accession: "0001628280-23-038053"
form_type: "8-K"
ticker: "XFOR"
cik: "0001501697"
company_name: "X4 Pharmaceuticals, Inc"
filed_at: "2023-11-09T23:59:59+00:00"
generated_at: "2026-06-08T06:36:13.127101+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# X4 Pharma: NDA accepted for mavorixafor in WHIM with PDUFA April 30, 2024; Q3 net loss $2.3M

## Summary
- FDA accepted NDA for once-daily oral mavorixafor in WHIM syndrome with Priority Review; PDUFA target April 30, 2024; eligible for Priority Review Voucher if approved.
- Ongoing Phase 2 chronic neutropenia data to be presented at ASH Dec 9-12, 2023; Phase 3 trial initiation expected 1H 2024.
- Q3 2023 cash, equivalents, and marketable securities totaled $142.7M; net loss of $2.3M (incl. $25.2M non-cash gain vs. $21.6M net loss in Q3 2022).
- Completed $115M debt facility with Hercules Capital; initial draw of $22.5M in August 2023.
- Appointed Christophe Arbet-Engels, MD, PhD as Chief Medical Officer in August 2023; added R. Keith Woods to Board of Directors in October 2023.

## SEC filing metadata
- accession: 0001628280-23-038053
- form_type: 8-K
- ticker: XFOR
- cik: 0001501697
- company_name: X4 Pharmaceuticals, Inc
- filed_at: 2023-11-09T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1501697/000162828023038053/0001628280-23-038053-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1501697/000162828023038053/xfor-20231109.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001628280-23-038053
- JSON: https://secwatch.observer/filing/0001628280-23-038053.json
- Plain text: https://secwatch.observer/filing/0001628280-23-038053.txt

## Key facts
- Earnings Releases
  X4 Pharmaceuticals, Inc reported the third quarter ended September 30, 2023 results: net income Net Loss: X4 reported a net loss of $2.3 million for the third quarter ended September 30, 2023.
  - Period: the third quarter ended September 30, 2023
  - Net income: Net Loss: X4 reported a net loss of $2.3 million for the third quarter ended September 30, 2023
  - Result: reported results
  source text: X4 Pharmaceuticals (Nasdaq: XFOR), a company driven to improve the lives of people with rare diseases of the immune system, today reported financial results for the third quarter ended September 30, 2023 and highlighted key recent and upcoming expected milestones.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1501697/000162828023038053/0001628280-23-038053-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.